Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 4/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MPI | P34949 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11059126 | 0.87 | CDC25B (0.60) | CDC25BKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL600272 | 0.84 | CDC25B (0.58) | CDC25BNQO2KDM4EKMT2AALDH1A1 | |
| SCHEMBL9297358 | 0.81 | CDC25B (0.55) | CDC25BNQO2KDM4EKMT2AALDH1A1 | |
| SCHEMBL5315678 | 0.81 | KDM4E (0.58) | CDC25BNQO2KDM4EKMT2AALDH1A1 | |
| SCHEMBL11156602 | 0.80 | ALDH1A1 (0.62) | KDM4EALDH1A1MAPTPOLBHSD17B10 | |
| SCHEMBL20127262 | 0.79 | CDC25B (0.61) | CDC25BKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL6266475 | 0.79 | CDC25B (0.56) | CDC25BNQO2KDM4EKMT2AALDH1A1 | |
| SCHEMBL27695227 | 0.78 | CA12 (0.55) | CDC25BNQO2KDM4EKMT2AALDH1A1 | |
| SCHEMBL30876155 | 0.77 | CDC25B (0.59) | CDC25BKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL30826563 | 0.77 | CDC25B (0.59) | CDC25BKDM4EKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166601-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240024276-A1 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-11813239-B2 | Compositions and methods for improving cardiac structure and/or function | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| EP-4212513-A1 | 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE DERIVATIVES AND RELATED COMPOUNDS AS NLRX1 LIGANDS FOR TREATING INFLAMMATORY DISEASES | LANDOS BIOPHARMA, INC. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11680045-B2 | NLRX1 ligands | LANDOS BIOPHARMA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3793979-B1 | 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE DERIVATIVES AND RELATED COMPOUNDS AS NLRX1 LIGANDS FOR TREATING INFLAMMATORY DISEASES | LANDOS BIOPHARMA INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20210322398-A1 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RES FOUND (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210309610-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210251938-A1 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-08-19 | — | — | US | disclosed |
| US-20180065945-A1 | SYNTHESIS OF NOVEL ANALOGS OF DIPTOINDONESIN G, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-03-08 | — | — | US | disclosed |
| US-9416156-B2 | Method of making biologically active alpha-beta peptides | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2337788-B1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | WISCONSIN ALUMNI RES FOUND (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20160039754-A1 | SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-11 | — | — | US | disclosed |
| US-20140315791-A1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-10-23 | — | — | US | disclosed |
| US-8642536-B2 | Method of making biologically active alpha-beta peptides | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130177981-A1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-20100234393-A1 | USE OF A VASOPEPTIDASE INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | BIOPROJET (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20100099185-A1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | LONGEVITY BIOTECH, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20070225268-A1 | METHOD TO TREAT NEOPLASMS VIA GADOLINIUM STEREOTACTIC SYNCHROTRON RADIATION | FOUNDATION, WISCONSIN ALUMNI RESEARCH | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322398-A1 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HDAC1, HDAC6, HDAC3 | CDC25B 2650/4885NQO2 2840/4885KDM4E 179/4885 |
| US-11680045-B2 | NLRX1 ligands | NLRP1, NLRP3, NOD1 | CDC25B 4524/4885NQO2 4194/4885KDM4E 3352/4885 |
| US-20210251938-A1 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | SDHA, SDHB, CS | CDC25B 520/4885NQO2 404/4885KDM4E 3054/4885 |
| US-20210309610-A1 | NLRX1 LIGANDS | NLRP1, NLRP3, NOD1 | CDC25B 4524/4885NQO2 4194/4885KDM4E 3352/4885 |
| US-20070225268-A1 | METHOD TO TREAT NEOPLASMS VIA GADOLINIUM STEREOTACTIC SYNCHROTRON RADIATION | GDA, UNG, GDI1 | CDC25B 2559/4885NQO2 2217/4885KDM4E 2362/4885 |
| US-20240166601-A1 | NLRX1 LIGANDS | NLRP1, NLRP3, NOD1 | CDC25B 4524/4885NQO2 4194/4885KDM4E 3352/4885 |
| US-11813239-B2 | Compositions and methods for improving cardiac structure and/or function | SDHA, SDHB, CS | CDC25B 520/4885NQO2 404/4885KDM4E 3054/4885 |
| US-20180065945-A1 | SYNTHESIS OF NOVEL ANALOGS OF DIPTOINDONESIN G, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HPGDS, DPP7, DPEP1 | CDC25B 284/4885NQO2 418/4885KDM4E 3016/4885 |
| US-20160039754-A1 | SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLP1R, GIPR, INSR | CDC25B 2773/4885NQO2 4114/4885KDM4E 2736/4885 |
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HDAC1, HDAC6, HDAC3 | CDC25B 2650/4885NQO2 2840/4885KDM4E 179/4885 |
| US-20100099185-A1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | IAPP, RNPEP, PTMA | CDC25B 2278/4885NQO2 3955/4885KDM4E 4836/4885 |
| US-20140315791-A1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | IAPP, RNPEP, PTMA | CDC25B 2278/4885NQO2 3955/4885KDM4E 4836/4885 |
| US-20130177981-A1 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES | IAPP, RNPEP, PTMA | CDC25B 2278/4885NQO2 3955/4885KDM4E 4836/4885 |
| US-20240024276-A1 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | SDHA, SDHB, CS | CDC25B 520/4885NQO2 404/4885KDM4E 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.